118 related articles for article (PubMed ID: 28121355)
21. Serum bone sialoprotein levels and bone metastases.
Uccello M; Malaguarnera G; Vacante M; Motta M
J Cancer Res Ther; 2011; 7(2):115-9. PubMed ID: 21768695
[TBL] [Abstract][Full Text] [Related]
22. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
24. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker.
Qian X; Li C; Pang B; Xue M; Wang J; Zhou J
PLoS One; 2012; 7(5):e37225. PubMed ID: 22615945
[TBL] [Abstract][Full Text] [Related]
25. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
[TBL] [Abstract][Full Text] [Related]
26. [When should we perform a bone scintigraphy in patients with new diagnosis of asymptomatic prostate cancer in order to detect bone metastasis?].
Márquez-López J; Gómez-Gómez E; Anaya-Henares F; Robles-Casilda R; Requena-Tapia MJ
Arch Esp Urol; 2015 Mar; 68(2):135-41. PubMed ID: 25774820
[TBL] [Abstract][Full Text] [Related]
27. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
28. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
29. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
[TBL] [Abstract][Full Text] [Related]
31. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
32. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
33. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.
Johansson M; Holmström B; Hinchliffe SR; Bergh A; Stenman UH; Hallmans G; Wiklund F; Stattin P
Int J Cancer; 2012 Jan; 130(1):129-37. PubMed ID: 21328341
[TBL] [Abstract][Full Text] [Related]
34. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
35. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
Thomsen FB; Christensen IJ; Brasso K; Røder MA; Iversen P
BJU Int; 2014 May; 113(5b):E98-105. PubMed ID: 24053601
[TBL] [Abstract][Full Text] [Related]
38. JOURNAL CLUB: Identification of Bone Metastasis With Routine Prostate MRI: A Study of Patients With Newly Diagnosed Prostate Cancer.
Woo S; Kim SY; Kim SH; Cho JY
AJR Am J Roentgenol; 2016 Jun; 206(6):1156-63. PubMed ID: 27043655
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.
Ishizuka O; Tanabe T; Nakayama T; Kawakami M; Kinebuchi Y; Nishizawa O
Int J Urol; 2005 Aug; 12(8):728-32. PubMed ID: 16174046
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer.
Waltregny D; Bellahcène A; Van Riet I; Fisher LW; Young M; Fernandez P; Dewé W; de Leval J; Castronovo V
J Natl Cancer Inst; 1998 Jul; 90(13):1000-8. PubMed ID: 9665149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
